Business, energy, technology, markets and global industry news from Business News Today

cutaneous T-cell lymphoma

PharmaDeviceNews cutaneous T-cell lymphoma
Innate Pharma’s lacutamab partnership with Sobi could unlock the TELLOMAK-3 Phase 3 trial and a potential accelerated approval pathway in T-cell lymphoma, with the licensing agreement carrying up to $580 million in potential value. Representative image.
Pharma & Biotech

What Sobi’s lacutamab licensing deal means for Innate Pharma and TELLOMAK-3

Innate Pharma’s Sobi deal brings $75m upfront and could unlock TELLOMAK-3, accelerated approval and global commercialization of lacutamab.

Read More
Representative image: Soligenix’s HyBryte trial setback has shifted investor and industry attention toward rare disease pipeline priorities, cash runway, and the future of SGX945 in Behçet’s disease.
Pharma & Biotech

What Soligenix’s Q1 update reveals about biotech risk after a failed confirmatory trial

HyBryte’s setback leaves Soligenix with cash, orphan assets, and a harder question. Can SGX945 reset the rare disease story?

Read More
Representative image: Citius Oncology’s Lymphir commercialisation push highlights the growing pressure on rare cancer biotech firms to turn FDA approvals and fresh funding into real-world treatment adoption.
Pharma & Biotech

Citius Oncology raises $36.5m, but can Lymphir convert rare cancer approval into commercial traction?

Lymphir has funding and FDA approval. Citius Oncology now faces the harder test of turning rare cancer access into real adoption.

Read More
Pharma & Biotech

How Soligenix is trying to turn tolerability and treatment logistics into a differentiated regulatory and commercial story

Soligenix published HyBryte versus Valchlor data in CTCL. Read what it changes for approval, adoption, and competitive positioning.

Read More